Prevalence, impact, and management of depression and anxiety in patients with Parkinson’s disease

Jenna B Renfroe1
Travis H Turner2,3
Vanessa K Hinson1,4
1Department of Neurology, Medical University of South Carolina, Charleston, SC, USA; 2Mental Health Service, Ralph H. Johnson VA Medical Centre, Charleston, SC, USA; 3Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA; 4Neurology Service, Ralph H. Johnson VA Medical Centre, Charleston, SC, USA

Abstract: Individuals with Parkinson’s disease (PD) exhibit higher rates of depression and anxiety than the general and other medically disabled populations. Evidence suggests that mood and anxiety symptoms are related to disease pathology. Rates of depression and anxiety in PD vary depending on how these symptoms are measured, but they are estimated to occur in up to 40% of patients. These conditions have adverse effects on patient and caregivers’ quality of life, level of disability, and mortality, with several studies suggesting greater contribution than motor symptom severity. Pharmacological and psychotherapeutic interventions, particularly in combination, have demonstrated efficacy in treating depression and anxiety in PD. However, additional randomized controlled trials are needed to better delineate when and how to best treat these disabling symptoms.

Keywords: Parkinson’s disease, depression, anxiety, prevalence, treatment

Introduction
Parkinson’s disease (PD) is most recognized by its cardinal symptoms of tremor, rigidity, bradykinesia, and postural instability. Also common are widespread non-motor symptoms, including rates of psychiatric symptoms that are disproportionate to both the general population and populations of comparable physical disability.1,2 Emotional changes in PD are hypothesized to be related to degradation and disruption of limbic-based basal ganglia circuitry1 and dysregulation of other neurotransmitter systems in PD.4 In addition, medications used to manage motor symptoms, particularly dopamine agonists, have well-established and fairly common psychiatric side effects, including behavioral disinhibition, visual hallucinations, and psychotic features. This review will focus on mood and anxiety disorders in PD, with the goal of providing PD clinicians and researchers an overview of the impact, prevalence and risk factors, etiology, and empirically supported treatments for mood and anxiety disorders in PD.

Impact
Numerous studies have shown that depression and anxiety negatively impact self-report of quality of life in PD,5-11 more so than motor symptom severity.7,8 One study found that depression has more than twice the impact of motor symptoms on overall health status in PD.12 Many studies report comparable effects of depression and anxiety on quality of life, but at least one suggested that anxiety may be the strongest predictor of quality of life in PD.13 In addition, psychiatric symptoms contribute significantly to level of caregiver burden and distress.14-16 One study found that the greatest predictor
of caregiver-endorsed depressive symptomology on the Geriatric Depression Scale (GDS) was the cared-for patient’s GDS score, suggesting that depressive symptoms in PD patients predict depressive symptoms in their spouses, arguably leading to overall greater health-care burden and cost. Depressive symptomology also leads to greater level of disability in PD.\(^\text{18–21}\) Although some studies have found anxiety to be a significant predictor of health status in PD (measured by the Parkinson Disease Questionnaire\(^\text{22}\)), depression seems to have a greater impact.\(^\text{22}\) Ravina et al\(^\text{23}\) demonstrated that depression can lead to earlier treatment of motor symptoms with medication in early PD. In addition, depression has been shown to be an independent predictor of mortality in PD, with a hazard ratio more than two times greater than age.\(^\text{23}\) One study showed a link between depressive symptoms and cardiac dysautonomia in PD patients, which may play a role in depression-related mortality in PD.\(^\text{24}\)

### Depression

#### Prevalence and risk factors

The prevalence of clinically significant depression in PD ranges from 7% to 40%, depending on whether strict diagnostic criteria or scores on mood scales are used for classification.\(^\text{25,26}\) Lower prevalence rates are reported when diagnostic status is based on clinical interview and Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnostic criteria are applied, whereas higher prevalence is reported in studies utilizing self-report scales and empirically established cutoffs to obtain depression rate estimates.\(^\text{25}\) The prevalence of PD patients meeting DSM-5 criteria for a major depressive disorder is estimated to be 17%; minor depression (generally characterized as clinically significant depressive symptoms that do not meet DSM criteria for major depression or dysthymia)\(^\text{27}\) is estimated to occur in 22% of patients, and dysthymia, or persistent low mood for a period of 2 years, is estimated to occur in 13% of patients.\(^\text{25}\) Estimated prevalence of suicidal ideation in PD is 23%, with estimated rate of completed suicide in PD of <1%–2%, which is not higher than the general older adult population.\(^\text{28–30}\)

Depression is common even in early, untreated PD, with an estimated prevalence of 14% in de novo, or medically untreated patients.\(^\text{31}\) Although no causative relationship is theorized, initiation of antidepressant treatment in older adults is associated with increased incidence of PD within 2 years,\(^\text{32}\) and diagnosis of a major depressive disorder is associated with a 3.2 odds ratio for PD onset within 1 year,\(^\text{33}\) suggesting that depression often predates the onset of clinical motor symptoms.

Risk factors for depression include the akinetic rigid and postural instability/gait difficulty (PIGD) subtype of PD.\(^\text{25,34–36}\) Some studies have found associations between depression and rapid disease progression,\(^\text{38,39,40}\) motor fluctuations,\(^\text{39}\) severity of illness,\(^\text{40}\) younger age of onset,\(^\text{38,39,41}\) and right-sided motor asymmetry.\(^\text{41–43}\) Although some studies show an association between disease severity and depression,\(^\text{9}\) it should be noted that associations between disease severity and depression may relate to the overlap between somatic symptoms of PD and somatic depressive symptomology, often measured by self-report questionnaires like the Beck Depression Inventory.\(^\text{44}\) Another recent study showed that a number of nonmotor factors most strongly predicted presence of depression in PD, including female sex, history of anxiety and/or depression, family history of depression, worse functioning on activities of daily living, and worse cognitive status.\(^\text{45}\)

#### Etiology

Abundant evidence suggests that PD depression is inherently related to the disease pathology. Clinically, depression often precedes the onset of PD motor symptoms by many years, contradicting the hypothesis that PD depression is simply an adjustment reaction to having a debilitating illness, although this is certainly an additional contributing factor for many individuals.\(^\text{33}\) Some investigators have proposed that depression in PD results from dysfunction of the serotonergic neurotransmitter system.\(^\text{46}\) PD depression has been related to neuronal loss in the dorsal raphe nuclei, reduced serotonergic binding in basal ganglia and prefrontal cortex, and lower serotonin levels in cerebrospinal fluid.\(^\text{47}\) Others have linked PD depression to dopaminergic dysfunction. The clinical correlate here is that depression and anxiety often worsen in the “off-state,” or at the end of dose of the patient’s dopaminergic medication.\(^\text{48}\) Findings from both animal\(^\text{49}\) and human studies\(^\text{50}\) have linked depression to impairment of the mesolimbic dopaminergic system and reduced activation of the ventral striatum,\(^\text{51}\) which is affected by PD as the disease progresses. Lastly, there is some evidence to suggest that inflammation may play a role in the pathogenesis of depression in PD, given that increased blood and cerebrospinal fluid markers of inflammation have been related to more severe depression symptoms in PD patients.\(^\text{52,53}\)

#### Treatment

#### Pharmacological management

Despite the prevalence and impact of depression in PD, there is a paucity of well-designed clinical trials for the treatment...
of PD depression. The largest placebo-controlled trial done to date compared the efficacy of paroxetine and venlafaxine XR in 115 patients with PD depression in a multicenter trial. Based on self-report from the Hamilton Depression Scale (HAM-D), at week 12 both treatment groups evinced statistically significant improvement over placebo (paroxetine =6.2, venlafaxine =4.2); the difference for paroxetine versus venlafaxine XR was not statistically significant. This is in contrast to results from a study by Menza et al comparing the efficacy of nortriptyline to that of paroxetine XR in 52 patients with PD depression. The treatment effect of nortriptyline was significant for both the overall change in the Hamilton Depression Scale and in the percent responders, whereas paroxetine CR was not. Both active treatments were well tolerated, but paroxetine CR had significantly more side effects than placebo and nortriptyline did not. The results of this trial bring up the question whether dual-reuptake inhibitors (acting on both serotonergic and noradrenergic transmission) such as nortriptyline are better suited for PD depression than pure serotonergic agents. Indeed, several small, controlled trials using selective serotonin reuptake inhibitors (SSRIs) failed to show efficacy in PD depression, although a recent meta-analysis showed significant effect of antidepressant treatment on depressive symptoms in PD when SSRI and serotonin–norepinephrine reuptake inhibitors (SNRI) treatment studies were combined.

Troeung et al recently published a meta-analysis of randomized, placebo-controlled trials for the treatment of anxiety and depression in PD. Of note, this analysis was limited to PD patients who met DSM criteria for depressive or anxiety disorder. Troeung et al found that citalopram, nortriptyline, paroxetine, and venlafaxine showed a small, statistically significant treatment effect in reducing depressive symptoms. In this study, the pooled effect size for studies of tricyclic antidepressants (TCAs) was large and significant ($d =$1.35, 95% CI $=0.19$–2.52), whereas the pooled effect size for SSRIs was not significant, again suggesting that different drug classes have variable efficacy in treating depression in PD. These results were generally consistent with two other recent meta-analyses of pharmacological treatment of depression in PD, suggesting superiority of TCAs to SSRIs in reducing PD depression symptoms. In contrast to Troeung et al’s findings, Bomasang-Layno et al did not find a significant effect of TCAs in the treatment of depression in PD but found that when stratifying SSRI/SNRI treatments versus other pharmacological treatments, the SSRI/SNRI treatment studies showed a significant effect on depressive symptoms in PD. Of note, Troeung et al also caution that the nonsignificant treatment effect in SSRIs may be due to the limited number of randomized controlled trials (RCTs) included for analysis (N=5) and highlighted the need for additional, carefully designed studies. Data from a Department of Veteran’s Affairs review on current practice among physicians treating PD patients shows that 63% of patients with PD and depression were taking SSRIs, while only 7% were taking TCAs. The US Parkinson Study group conducted a survey among physicians and found that 51% used SSRIs as first-line treatment for PD depression. Likely, this practice is based on safety concerns in regards to the use of TCAs, mainly related to their potential for cardiac conduction delay and anticholinergic properties. Finally, a meta-analysis of RCTs on the use of pramipexole, a dopamine agonist, to treat depressive symptoms found that the use of pramipexole significantly improved mood and motivation symptoms.

**Behavioral therapies**

Meta-analyses on the effect of behavioral treatments for depression in PD consistently show positive, robust effects. Dobkin et al used a cognitive behavioral therapy (CBT) approach specifically tailored for Parkinson patients in the treatment group (N=41), compared to a clinical monitoring control group (N=39). Those in the CBT group showed greater reduction in depressive symptoms (56% responders, characterized by a greater than 50% decrease in depressive symptoms) compared to the control group (8% responders). Those in the CBT group also showed greater improvements on measures of anxiety, quality of life, coping, and Parkinson’s disease symptom ratings (Unified Parkinson’s Disease Rating Scale motor score), and treatment responses were maintained at 1 month posttreatment. To date, the only other RCT (with a nonpharmacological control group) of CBT for the treatment of depression in PD also showed a positive effect of CBT on depressive symptoms, anxiety, and quality of life. Of note, this study employed telephone-delivery of CBT, used a supportive treatment control group, and only three patients completed treatment in each of the groups. Recent evidence also suggests that group CBT can be effective in treating depression and anxiety symptoms in PD patients.

A recent meta-analysis suggested that, in addition to CBT, psychodynamic behavioral therapy for depression in PD is also effective. The authors of this meta-analysis also suggest that psychodynamic therapy may have larger effects on depressive symptoms than CBT; however, these results may have been biased by the nature of studies included in this meta-analysis. Specifically, most of the CBT studies included in the
analysis (4/6) compared CBT plus pharmacological treatment to pharmacological treatment alone, whereas most of the psychodynamic therapy studies (4/6) compared psychodynamic treatment to a relatively inactive control group. Importantly, of studies that have compared the use of behavioral therapy plus pharmacological treatment to pharmacological treatment alone, all have found that a combination of behavioral treatment with pharmacological therapy is superior to treatment with a pharmacological agent alone.70

**Alternative treatments**

Repetitive transcranial magnetic stimulation (rTMS) has received attention for its potential in treating depressive symptoms in PD.71–79 A recent meta-analysis of RCTs for the use of rTMS for the treatment of depressive symptoms in PD found rTMS to be superior to sham treatment in reducing depressive symptoms in PD, and to have similar efficacy as SSRIs, with the possible benefit of simultaneous improvement in motor symptoms.80 Another meta-analysis found the effect of rTMS on depression in PD to be non-significant, based on the two existing RCTs. Based on the current state of the literature, Shirota et al72 made a “weak recommendation” in favor of high-frequency rTMS of the left dorsolateral prefrontal cortex for the treatment of depressive symptoms in PD.

On the contrary, one of two nonpharmacological treatments for depression in PD in Troeung et al’s86 meta-analysis that resulted in a larger treatment effect compared to studies of pharmacotherapy was an RCT of OMEGA-III supplementation for depression in PD.80,81 After 3 months of supplementation, those receiving OMEGA-III (N=14) reported decreased depression compared to the placebo group (N=15), with 42% of patients in the OMEGA-III group showing greater than 50% reduction in depressive symptoms, compared to 6% in the placebo group. Of note, this study was specifically in PD patients who met criteria for a major depressive episode, and those with cognitive impairments were excluded.

Lastly, case reports have suggested that electroconvulsive therapy (ECT) may be successful in treating severe, medication-refractory depressive disorders in PD, especially those that result in severe behavior disruption or psychosis, including cases concomitantly treated with deep brain stimulation for treatment of their motoric PD symptoms.83,84 Interestingly, ECT has been observed to also improve motor symptoms in these patients. However, the existing literature on ECT in PD patients consists only of case studies;59 therefore, more research in the form of RCTs is needed before ECT would be a recommended therapy for psychiatric symptoms in PD.

**Anxiety**

**Prevalence and risk factors**

Estimated prevalence of anxiety disorders in PD is approximately 40%,135–87 and it is 25%–29% when DSM criteria for anxiety disorders are applied.3,88 The most common DSM anxiety disorders to occur in PD are generalized anxiety disorder (GAD), panic disorder, and phobias.5,85,87 As in the case of depression in PD, evidence suggests that anxiety symptomology often predates and increases the risk of clinical diagnosis of PD.89–91 One study found a direct correlation between severity of anxiety and increased risk for onset of PD.91 Studies have consistently found an association between anxiety, younger age of onset of PD, and presence of motor fluctuations.5,85,92,93 In addition, there seems to be a link between wearing off of dopaminergic medications and increased anxiety.48,93,94

**Etiology**

Anxiety in PD may be driven by the psychosocial stress of having the disease,95 including social shame related to tremulousness and disability, being dependent on another person, fear of falling, and motor fluctuations.87,95,96 However, there is also evidence that a certain proportion of anxiety symptomatology may be due to reduced dopaminergic inhibition of the locus coeruleus, resulting in excess noradrenergic activity.97 The same may be true as it pertains to dopaminergic influences on the amygdala in PD.87 Anxiety in PD may generally be related to abnormalities in norepinephrine, serotonin, dopamine, and γ-aminobutyric acid (GABA) neurotransmitters, which have been implicated in the pathogenesis of anxiety98,99 and have also been found to be abnormal in PD.4 Abnormal functioning of the raphe nucleus and the locus coeruleus, which are both affected by the pattern of Lewy body deposition proposed by Braak staging,100 may also play a role in the pathogenesis of anxiety in PD.97

**Treatment**

**Pharmacological management**

With respect to RCTs that assessed pharmacological effects on anxiety in addition to depression in PD, all SSRI and TCA interventions resulted in large and statistically significant reductions in anxiety, with effect sizes ranging from 0.93 to 1.98, with the exception of paroxetine.86 In addition, atomoxetine was also noted to have a significant effect in lowering anxiety symptoms.101 As in the case of depressive symptoms, TCAs showed a superior effect on anxiety than SSRIs.86 However, as discussed previously, the use of TCAs clinically is somewhat eschewed owing to their unfavorable side effect profile.
Behavioral therapies
Although there have been no RCTs to investigate cognitive behavioral therapy specifically for anxiety disorders in PD, the two trials that investigated CBT for PD depression also collected self-report of anxiety symptoms in these patients. In both studies, CBT, whether delivered in person or via telephone, resulted in significantly decreased anxiety symptoms in PD patients.57,102

Alternative treatments
Marino and Friedman103 describe two cases of severe, medication-refractory anxiety in PD that responded positively to ECT. Both patients also showed significant improvement in motor symptoms following ECT therapy. Whether results were maintained in these patients is unknown.

Summary and conclusion
As summarized in Table 1, depression and anxiety are present in up to 40% of PD patients and likely relate to the underlying neuropathology of the disease. These psychiatric conditions can present prior to motor manifestation of the disease and impact variables such as level of disability, quality of life, caregiver burden, and mortality. Studies have shown limited support for treatment of PD depression with SSRIs and have suggested higher efficacy of TCAs in the treatment of PD depression; however, most clinicians choose to prescribe SSRIs because of high side effect profiles of TCA. SNRIs such as venlafaxine and the dopamine agonist pramipexole have shown promise in treating depression symptoms in PD. Studies have shown support for both SSRI and TCA treatment of anxiety in PD, and one study showed support for atomoxetine in the treatment of PD anxiety. Evidence suggests that CBT, or a combination of CBT and psychotropic medication, may be most effective in treating mood and anxiety symptoms in PD. Lastly, since depression and anxiety can present very early in the disease process, future studies may want to focus on early intervention strategies for these conditions.

Disclosure
JBR, THT, and VKH receive salary support from the Michael J. Fox Foundation for an investigator-initiated research study. THT receives salary support from the Congressionally Directed Medical Research Program / Department of Defense (CDMRP/DOD) for an investigator-initiated randomized controlled trial and salary support from Aker BioMarine for an investigator-initiated randomized controlled trial.

Table I Summary (with literature-based references) of prevalence, risk factors, etiological considerations, and evidence-based treatments for depression and anxiety in Parkinson’s disease

<table>
<thead>
<tr>
<th>Depression</th>
<th>Anxiety</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prevalence</strong></td>
<td>-40%25,27</td>
</tr>
<tr>
<td><strong>Risk factors</strong></td>
<td>Motor fluctuations54,56,72,73,104</td>
</tr>
<tr>
<td>Motor fluctuations5,9,14 Motor fluctuations9,14 Younger disease onset88,89,91,92 Right-sided motor asymmetry41-43 Female sex46 History of premorbid depression46 Family history of depression46 Worse disability/poor cognition46</td>
<td></td>
</tr>
<tr>
<td><strong>Neurobiological components</strong></td>
<td>Disinhibition/dysfunction of amygdala47 Disinhibition/dysfunction of locus coeruleus57,97 Dysfunction of raphe nucleus47 Abnormalities in norepinephrine, serotonin, dopamine, and γ-aminobutyric acid (GABA) neurotransmitters4,87</td>
</tr>
<tr>
<td>Mesolimbic dopaminergic dysfunction</td>
<td>Neuroinflammation52,53</td>
</tr>
<tr>
<td>Mesocortical dopaminergic dysfunction</td>
<td></td>
</tr>
<tr>
<td>Serotonergic dysfunction47</td>
<td></td>
</tr>
<tr>
<td><strong>Psychosocial components</strong></td>
<td>Adjustment to chronic illness/disability</td>
</tr>
<tr>
<td>Adjustment to chronic illness/disability Social shame45 Motor fluctuations45 Fear of falling25</td>
<td></td>
</tr>
<tr>
<td><strong>Pharmacologic treatments</strong></td>
<td>SSRIs58,60</td>
</tr>
<tr>
<td>SSRIs58,60</td>
<td>TCA58,60</td>
</tr>
<tr>
<td>TCA58,60</td>
<td>Atomoxetine101</td>
</tr>
<tr>
<td>Pramipexole65</td>
<td></td>
</tr>
<tr>
<td><strong>Nonpharmacological treatments</strong></td>
<td>CBT19,30</td>
</tr>
<tr>
<td>CBT19,30</td>
<td>ECT101</td>
</tr>
<tr>
<td>Omega-320,81</td>
<td>rTMS19,20,72,80</td>
</tr>
<tr>
<td>rTMS19,20,72,80</td>
<td>ECT101</td>
</tr>
<tr>
<td>rTMS19,20,72,80</td>
<td>ECT101</td>
</tr>
</tbody>
</table>

Abbreviations: PIGD, postural instability/gait disorder; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; CBT, cognitive behavioral therapy; rTMS, repetitive transcranial magnetic stimulation; ECT, electroconvulsive therapy.

VKH has received research grant support from the National Institute of Health, Accorda Pharmaceuticals, Abbvie, Biotie Therapies, and the Barmore fund.

References


